Speciality Medicines (BOM:544738) Other Current Liabilities: ₹52.9 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:544738 Speciality Medicines Ltd BOM:544738
21 GF Score
Price ₹156.65
! 3 Warning Signs
View Full Analysis

What is Speciality Medicines Other Current Liabilities?

Speciality Medicines BOM:544738 -6.76% 21 Other Current Liabilities is ₹52.9 Mil as of Mar. 2026. GuruFocus rates BOM:544738 with a GF Score™ of 21/100. The stock has 3 warning signs investors should review.

Speciality Medicines's other current liabilities for the quarter that ended in Mar. 2026 was ₹52.9 Mil.

Speciality Medicines's quarterly other current liabilities increased from Mar. 2024 (₹20.2 Mil) to Mar. 2025 (₹30.8 Mil) and increased from Mar. 2025 (₹30.8 Mil) to Mar. 2026 (₹52.9 Mil).

Speciality Medicines's annual other current liabilities increased from Mar. 2024 (₹20.2 Mil) to Mar. 2025 (₹30.8 Mil) and increased from Mar. 2025 (₹30.8 Mil) to Mar. 2026 (₹52.9 Mil).

Speciality Medicines Other Current Liabilities Related Terms

Speciality Medicines Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Speciality Medicines's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Speciality Medicines Other Current Liabilities Chart

Speciality Medicines Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Liabilities
14.04 18.18 20.19 30.79 52.86

Speciality Medicines Semi-Annual Data
Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Liabilities 14.04 18.18 20.19 30.79 52.86
BOM:544738
21GF Score
Speciality Medicines Ltd BOM:544738
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Speciality Medicines Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of ₹52.9 Mil mean?
Speciality Medicines (BOM:544738) has a Other Current Liabilities of ₹52.9 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Speciality Medicines.
Is Speciality Medicines' Other Current Liabilities too high?
Speciality Medicines' current Other Current Liabilities is ₹52.9 Mil. Overall, Speciality Medicines has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Speciality Medicines' Other Current Liabilities compare to ZTS?
Speciality Medicines' Other Current Liabilities of ₹52.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Speciality Medicines. Speciality Medicines's current Other Current Liabilities is ₹52.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Speciality Medicines stock overvalued right now?
Speciality Medicines (BOM:544738) has a current Other Current Liabilities of ₹52.9 Mil. The current Other Current Liabilities is ₹52.9 Mil. Speciality Medicines' overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Speciality Medicines (BOM:544738), the current Other Current Liabilities is ₹52.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Speciality Medicines Business Description

Address 20 Mahakali Caves Road, Unit 27, Ground Floor, Andheri Sainath Premises Co Soc, Andheri (East, Mumbai, MH, IND, 400093
Speciality Medicines Ltd is engaged in the marketing and distribution of finished formulations of specialty pharmaceutical products, comprising oral and injectable medications used in the treatment of complex and chronic medical conditions in therapeutic areas like oncology, immunology, neurology and rare diseases. Its product range includes various dosage forms such as tablets, capsules, syrups, injections, infusions, inhalers, sprays, and topical formulations. The company operates through two business models: (a) Manufacturing, through contract manufacturing basis, and (b) Marketing and distribution of specialty pharmaceutical products sourced from manufacturers. The majority of the company's revenue is derived from the sale of its projects, mainly through exports to other countries.
21GF Score

Get the complete analysis for BOM:544738

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹156.65
Price